1-20 of 43
Amitkumar Mehta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta
Journal: Blood
Blood (2024) 144 (Supplement 1): 3449.
https://doi.org/10.1182/blood-2024-205205
Published: 2024
Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 95.
https://doi.org/10.1182/blood-2024-194807
Published: 2024
Journal Articles

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Lilly Meier, Elizabeth Budde, Liffy Indu Cherian, Matthew Matasar, Amitkumar Mehta, Nilanjan Ghosh, Ashley Lile, Elana Plotkin, Nicole A Colwell, Molly Kisiel
Journal: Blood
Blood (2024) 144 (Supplement 1): 7945.
https://doi.org/10.1182/blood-2024-194129
Published: 2024
Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

L. Elizabeth Budde, Adam J Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Hao Wu, Iris To, Michael C. Wei, Julio C. Chavez
Journal: Blood
Blood (2023) 142 (Supplement 1): 613.
https://doi.org/10.1182/blood-2023-174209
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3505.
https://doi.org/10.1182/blood-2023-178109
Published: 2023
Journal Articles

Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens

Star Ye, Christian Harmon, Nadia Anabtawi, Clare Ubersax, Abigail Tucker, Gaurav Goyal, Lauren Shea, Mayur Narkhede, Amitkumar Mehta, Purnima Singh, Grant Williams, Smita Bhatia, Smith Giri
Journal: Blood
Blood (2022) 140 (Supplement 1): 3779–3780.
https://doi.org/10.1182/blood-2022-163653
Published: 2022
Journal Articles

Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma

Mayur Narkhede, Lauren Shea, Gaurav Goyal, Amitkumar Mehta
Journal: Blood
Blood (2022) 140 (Supplement 1): 9358–9360.
https://doi.org/10.1182/blood-2022-164670
Published: 2022
Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly
Journal: Blood
Blood (2022) 140 (Supplement 1): 12742–12743.
https://doi.org/10.1182/blood-2022-159282
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Jonathan W. Friedberg, Carrie A. Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M. Reagan, Mark Hertzberg, Piotr Smolewski, Huilai Zhang, Catherine Thieblemont, Bei Hu, Gustavo Fonseca, Won-Seog Kim, Maurizio Martelli, Amitkumar Mehta, Avrita Campinha-Bacote, Mark Yan, Jamie Hirata, Matthew Sugidono, Calvin Lee, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6623–6626.
https://doi.org/10.1182/blood-2022-157761
Published: 2022
Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani
Journal: Blood
Blood (2022) 140 (Supplement 1): 3728–3730.
https://doi.org/10.1182/blood-2022-167772
Published: 2022
Journal Articles

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Pamela B. Allen, Subir Goyal, Swaminathan P. Iyer, Sai Talluru, Auris Huen, Irl Brian Greenwell, Jane Scribner, Shel Speegle, Tim Niyogusaba, Sunil Rangarajan, Amitkumar Mehta, Colin B. O'Leary, Anne W. Beaven, Jeffrey M. Switchenko, Amy Ayers, Safiyyah Bhatti, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Francine M. Foss, Mary Jo Lechowicz, Sima Rozati
Journal: Blood
Blood (2022) 140 (Supplement 1): 9431–9433.
https://doi.org/10.1182/blood-2022-170921
Published: 2022
Journal Articles

Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

Muthu Veeraputhiran, Amitkumar Mehta, Alvaro J. Alencar, Dipenkumar Modi, Timothy J. Voorhees, Mayur Narkhede
Journal: Blood
Blood (2022) 140 (Supplement 1): 12089–12091.
https://doi.org/10.1182/blood-2022-158595
Published: 2022
Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park
Journal: Blood
Blood (2022) 140 (Supplement 1): 4577–4578.
https://doi.org/10.1182/blood-2022-167194
Published: 2022
Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Amitkumar Mehta, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane, Guillermo Rodriguez, Michal Taszner, Parameswaran Venugopal, Vittorio Ruggero Zilioli, Fred Zheng, Douglas J DeMarini, Wei Jiang, Pier Luigi Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 382.
https://doi.org/10.1182/blood-2021-147867
Published: 2021
Journal Articles

No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis

Pamela Allen, Subir Goyal, Irl Brian Greenwell, Jane Scribner, Sunil Rangarajan, Amitkumar Mehta, Colin Burke O'Leary, Tim Niyogusaba, Auris Huen, Jeffrey M. Switchenko, Erica Shantha Tarabadkar, Amy Ayers, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Swaminathan P Iyer, Mary Jo Lechowicz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2441.
https://doi.org/10.1182/blood-2021-151911
Published: 2021
Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2488.
https://doi.org/10.1182/blood-2021-152225
Published: 2021
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings
Journal: Blood
Blood (2021) 138 (Supplement 1): 2479.
https://doi.org/10.1182/blood-2021-147780
Published: 2021
Journal Articles

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta
Journal: Blood
Blood (2021) 138 (Supplement 1): 2493.
https://doi.org/10.1182/blood-2021-147292
Published: 2021
Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson
Journal: Blood
Blood (2021) 138 (Supplement 1): 44.
https://doi.org/10.1182/blood-2021-147778
Published: 2021
Journal Articles

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Amitkumar Mehta, Wael Harb, Claire Xu, Yuan Meng, Linda Lee, Vivian Yuan, Zhengyi Wang, Pengfei Song, Joan Huaqiong Shen, Ajay K Gopal
Journal: Blood
Blood (2021) 138 (Supplement 1): 3542.
https://doi.org/10.1182/blood-2021-150606
Published: 2021